NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that revenues for the first quarter increased 185 percent year over year, led by reagents revenues.

For the period ended March 31, total revenues increased to $2.2 million from $758,000, as product revenues rose to $2.1 million from $693,000 while license and other revenues dropped to $39,000 from $65,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.